Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
BUENA, N.J., March 05, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Raymond James 39th Annual Institutional Investors Conference. The Conference is taking place March 4-7, 2018 at the J.W. Marriott Grande Lakes, Orlando, FL.
Jason Grenfell-Gardner, President and CEO and Damian Finio, Chief Financial Officer of Teligent, Inc. will present on Wednesday March 7th at 9:15 a.m. ET.
The presentation will be webcast and will be accessible online on the investors section of the Company's website at http://www.teligent.com. A replay will be available for 30 days.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Martin Wilson
Teligent, Inc.
856-336-9120
www.teligent.com
